Company intelligence / Profile preview

Diagene

Reinach, Basel-Landschaft, Switzerland

Ownership: Private
Development stage: Other

Overview

Diagene is a Swiss biotechnology company specializing in molecular diagnostics for cardiovascular diseases. The company is best known for its focus on Familial Hypercholesterolemia (FH), providing genetic testing services to identify mutations in the LDLR, APOB, and PCSK9 genes. Diagene's services enable early diagnosis and cascade screening for at-risk family members, facilitating proactive management of high cholesterol and heart disease risk. Beyond FH, the company offers diagnostic solutions for other metabolic and genetic conditions, supporting personalized medicine in the cardiovascular field.

Therapeutic areas: CardiovascularMetabolic Disorders
Modalities: Diagnostic testGenetic testing
Industry: Molecular Diagnostics

Partnerships

Swiss Society of CardiologyEuropean Atherosclerosis Society

Beyond the preview

Go deeper on Diagene.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Diagene.

Explore the full profile